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Chimerism is universally used to monitor engraftment after hematopoietic SCT (HSCT); it is valuable for predicting graft failure, rejection as well as relapses in malignant diseases. Chimerism kinetics are clinically significant and are influenced by the type of conditioning regimens and transplanted diseases. After reduced-intensity conditioning (RIC), dynamics to reach full donor chimerism seem to be slower compared with myeloablative conditioning; however, most patients obtain full chimerism within the first 6 months. 1 Underlying diseases might influence significantly the kinetics of chimerism. In aplastic anemia, stable mixed chimerism provided similar survival advantage to complete donor chimerism compared with progressive mixed chimerism; 2 however, in AML conditioned with myeloablative or RIC, full donor chimerism is related with a lower risk of relapse and mortality. 3 Knowledge of the clinical significance of chimerism kinetics over 41 year after RIC-HSCT is scarce; hence, we aimed to evaluate in a population transplanted due myeloid neoplasms, the impact on outcome of chimerism kinetics.
All patients with acute leukemia or chronic myeloid neoplasm transplanted with RIC between 1998 and 2013 at the Hematology Division of the University of Basel (Basel, Switzerland) were included in this retrospective study. After allogeneic HSCT, all recipients were regularly followed up at 1, 3, 6 and 12 months, and thereafter at yearly intervals or more often when indicated. These consultations included assessment of past history, clinical examination, standard laboratory tests and chimerism of peripheral blood. Leukocyte subpopulation chimerism of CD+ (T lymphocytes) and CD66+ (granulocytes) cells was performed in patients without full donor chimerism or under persistent immunosuppression. Patients provided written informed consent to have their data reported in an anonymous way to the register. Clinical surveillance of HSCT recipients was approved by the local Institutional Review Board. Patient characteristics, HSCT conditioning regimens and clinical outcome data were collected prospectively and stored in the local institution database registry.
Chimerism was analyzed by PCR-based DNA amplification of nine different STR loci. Separation of CD3+ and myeloid cells was performed with RoboSep (STEMCELL Technologies, Inc., Vancouver, BC, Canada). The results of subpopulation chimerism were provided only if the selection resulted in a purity of 460%. Full donor chimerism was considered when the donor contribution was ⩾ 95%. For this study, patients were classified according to chimerism kinetics. Chimerism A: patients with either full donor chimerism or mixed chimerism converting to full chimerism. Chimerism B: patients with either stable mixed, full chimerism converting to mixed, loss or absence of donor chimerism. We compared the impact of chimerism on survival, acute and chronic GVHD, relapse and TRM.
Outcomes were assessed using the Kaplan-Meier estimator and compared among the chimerism groups using the log-rank test.
To identify independent prognostic risk factors, a multivariate linear regression analysis using a stepwise backward elimination of significant variables was performed. Differences between the results of comparative tests were considered significant if the twosided P-value was o0.05. Statistical analysis was performed by using SPSS statistical software (SPSS for Windows, Release 17, SPSS, Chicago, lL, USA).
Seventy-seven patients with 81 transplants were included (Table 1) . Median age was 61 years (range 10-70), 52 patients (68%) were males, 35 patients (45%) had acute leukemia and 42 (55%) had chronic myeloid malignancy, 46 patients (60%) had advanced disease stage before HSCT, 59 (77%) were conditioned with fludarabine and 2 Gy TBI, 71 (92%) received PBSC as the stem cell source, 38 patients (49%) were transplanted from a sibling donor and 39 (51%) from an alternative donor (37 with an unrelated donor and 2 with a mismatched related donor). At 3 years, TRM was 26 ± 14%, grade II-IV acute GVHD 32 ± 11% and chronic GVHD of any grade 75 ± 14%. Full blood chimerism was available for all patients, CD3+ and CD66+ chimerism only in 49 and 32 patients, respectively; we focused the analysis therefore on full blood chimerism. During the follow-up, stable full or mixed converted to full chimerism (group A) was observed in peripheral blood of 50 patients (61.7%). Group B included never engrafted (n = 4), never reached a full chimerism (n = 22) and loss of full chimerism (n = 5). From the 22 patients who never reached a full chimerism, 3 are alive and 19 are dead (13 relapsed and 6 early death). In six patients, the decrease of the whole blood donor type chimerism was observed without concomitant relapse of the underlying disease. A mixed type chimerism anticipated the relapse in four cases: the delay between decrease of donor type chimerism and relapse was 2 months in one case, 5 months in three cases and 6 months in one case. In two cases, the loss of graft was not directly related with relapse of the leukemia. One of these cases underwent a second HSCT 1 year after graft loss without any evidence of relapse. In the second case, owing to the graft loss, a second HSCT was performed 3 months afterward. After the second HSCT, a graft loss occurred again with autologous regeneration. A relapse of the AML occurred 96 months later. OS of all the patients at 3 years was 44 ± 12% ( Figure 1a ). For patients with persisting full donor chimerism (chimerism A), 3-year OS was 63 ± 16%, whereas for patients who did not reach or lost full donor chimerism (chimerism B), OS was 23 ± 16% (P o 0.0001) (Figure 1c) . At 3 years the probability of relapse was 49 ± 13% ( Figure 1b) . The probability of relapse for patients with chimerism A was 25 ± 14% vs 86 ± 14% for patients with chimerism B (P o 0.0001) (Figure 1d ). Acute ( Figure 1e ) and chronic GVHD and TRM ( Figure 1f) were not different between both groups. In multivariate analysis, full donor chimerism, early-stage disease at HSCT, type of disease (myelodysplastic syndromes/myeloproliferative neoplasms vs acute leukemia) and matched sibling donor were associated with better OS (Table 2) .
In this study, we evaluate the chimerism kinetics to predict the outcome of patients with acute leukemia or chronic myeloid malignancies treated with RIC-HSCT. Unlike what was described in aplastic anemia, 2 persistent mixed chimerism 3 or loss of donor type chimerism was associated with disease relapse and adverse outcome in myeloid neoplasms. Previous communications showed that delayed full donor T-cell chimerism in myeloid malignancies (24 patients) was related to a higher relapse rate. 4 We show here the relevance of full blood chimerism follow-up in patients transplanted with RIC. The majority of patients with persistent mixed donor chimerism had a poor prognosis with respect to relapse and survival. Reaching full donor type blood chimerism after RIC-HSCT is therefore strongly predictive of a favorable outcome. Performing chimerism analysis from whole blood is much easier for a routine hematology laboratory as samples need less manipulation and results are not dependent on the purity of cell population as it is in split chimerism. Furthermore, most published studies evaluate chimerism at one time point to predict the outcome, 4 ,5 whereas here we show that analyzing the results in a longitudinal way could provide significant information. In this population, stable full donor chimerism, early-stage disease at HSCT and being transplanted with a matched sibling donor were strong predictors for better OS. Nowadays, regular evaluations of the remission state by BM analysis tend to be performed less frequently after HSCT, therefore the dynamics of full blood chimerism together with molecular markers represent an attractive follow-up option in these patients.
This study has some limitations such as we focused on myeloid neoplasms, the evaluated population has a heterogeneous spectrum of diseases including acute leukemia and chronic myeloid diseases in advanced stages; furthermore, although all patients were transplanted with a reduced-intensity modality and most of them received a fludarabine/TBI 2 Gy scheme, the conditioning regimens were not completely homogeneous. These aspects might have had an influence on the results.
In conclusion, full donor type peripheral blood chimerism predicts survival advantage in patients with leukemia and chronic myeloid malignancies after RIC allogeneic HSCT.
